VistaGen Therapeutics Stock Price. Everything You Need To Know About The VistaGen Therapeutics Stock!

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, committed to developing and commercializing next-generation medications for patients with diseases and disorders involving the central nervous system (CNS). With 32 full-time employees, the company is focused on improving treatment options beyond the current standard of care for anxiety, depression, and other CNS disorders.

VistaGen Therapeutics has a diverse pipeline of product candidates, including PH94B, a neuroactive nasal spray with the potential to treat multiple anxiety disorders that is preparing for Phase III clinical trial for social anxiety disorder (SAD), PH10, a neuroactive nasal spray that is planning for Phase 2b development as a stand-alone treatment for major depressive disorder (MDD), and AV-101, which the company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID), and epilepsy.

AV-101 is an oral prodrug of 7-chloro-kynurenic acid (7-Cl-KYNA), which is a potent and selective full antagonist of the glycine co-agonist site of the N-methyl-D-aspartate receptor (NMDAR) that inhibits the function of the NMDAR, an ionotropic glutamate receptor in the brain. The company’s innovative product candidates offer potential new treatment options for patients suffering from CNS disorders.

Since going public in 2010, VistaGen Therapeutics has been dedicated to advancing its pipeline and improving the lives of patients with CNS disorders. However, as with any investment, it’s important to stay informed about the latest developments in the company, including any changes to its stock price, market cap, or other key financial indicators. By staying up-to-date with these factors, investors can make informed decisions about their investments and potentially reap the rewards of a well-performing stock.